Long-term remission with certolizumab pegol in Crohn's disease

Gary R. Lichtenstein(University of Pennsylvania), William J. Sandborn(University of San Diego), Ian C. Lawrance(The University of Western Australia), Stephen B. Hanauer(Northwestern University), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Ralph Bloomfield(AstraZeneca (United Kingdom)), Oskar Kaaber Thomsen(University of Copenhagen)
Inflammatory Bowel Diseases
January 1, 2011
10.1093/ibd/17.supplement1.s51b
Cited by 0

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k